Dopamine agonists act directly on striatal dopamine receptors without requiring conversion by surviving nigrostriatal terminals. This pharmacological independence from terminal density gives them a theoretical advantage over levodopa in advanced disease, and their longer plasma half-lives produce more continuous receptor stimulation — reducing, though not eliminating, the risk of motor complications compared with pulsatile levodopa therapy. The clinically critical division within this class is between ergot-derived and non-ergot agonists, a distinction that today determines which agents are still in routine use.
Ergot-derived dopamine agonists — including bromocriptine, pergolide, lisuride, and cabergoline — were the first dopamine agonists introduced into PD pharmacotherapy, beginning with bromocriptine in the 1970s. They are structural derivatives of ergotamine and share the tetracyclic ergoline ring system. Their dopamine receptor activity is supplemented by activity at serotonin (5-HT2B) receptors in cardiac valvular fibroblasts and at adrenergic receptors, contributing to their adverse effect profiles. Pergolide and cabergoline were both withdrawn or restricted in most markets after the discovery that 5-HT2B receptor activation in heart valve interstitial cells promotes fibroblast proliferation, producing the same pattern of restrictive valvulopathy seen with fenfluramine and methysergide.1 Echocardiographic studies demonstrated clinically significant valve regurgitation in up to 20–30% of patients receiving pergolide or cabergoline at doses used for PD, with risk increasing with cumulative dose. Bromocriptine, which has lower 5-HT2B affinity, has a lower but non-negligible valvulopathy risk and is now rarely used for PD. Ergot agonists as a class should not be initiated as new treatment for PD, and patients remaining on cabergoline require periodic echocardiographic surveillance if treatment cannot be changed.
Non-ergot dopamine agonists — pramipexole, ropinirole, and rotigotine — are structurally distinct from ergot alkaloids and do not activate 5-HT2B receptors at therapeutic concentrations, eliminating the fibrotic valvulopathy risk. They constitute the current standard for dopamine agonist therapy in PD. Pramipexole and ropinirole are D2 and D3 receptor preferential agonists, with greater relative affinity for D3 than for D2 receptors. D3 receptors are expressed at high density in limbic areas including the nucleus accumbens and prefrontal cortex, as well as in the striatum, and this limbic D3 activity is thought to contribute both to the antidepressant-like effects that some patients experience and to the reward pathway dysregulation underlying impulse control disorders and dopamine dysregulation syndrome.2 Rotigotine is a non-ergot agonist with a broader receptor profile, acting at D1, D2, D3, and D4 receptors, as well as partial agonism at 5-HT1A receptors; it does not activate 5-HT2B receptors.
The receptor pharmacology of dopamine agonists contrasts with levodopa in two clinically important ways. First, all currently used agonists act primarily at D2-family receptors (D2, D3, D4), and none reliably stimulates D1 receptors at therapeutic concentrations, whereas levodopa-derived dopamine acts at both D1 and D2 receptors in approximately physiological proportions. This D1 deficit is the primary reason dopamine agonists produce inferior motor control compared with levodopa at equivalent disease stages: D1 receptor activation is essential for full expression of the direct pathway motor benefit, and its absence produces a ceiling effect on agonist motor efficacy. Second, dopamine agonists produce a more continuous and sustained receptor stimulation than immediate-release levodopa, reflecting their longer half-lives (8–12 hours for pramipexole and ropinirole immediate-release; 24 hours for extended-release formulations and rotigotine patch). This more continuous stimulation is associated with lower rates of dyskinesia induction compared with levodopa at equivalent motor benefit, particularly in the first several years of treatment.3
Pergolide and cabergoline activate 5-HT2B receptors on cardiac valve fibroblasts, inducing a restrictive valvulopathy with regurgitation indistinguishable from that caused by fenfluramine. Risk is dose-dependent and cumulative. Echocardiographic abnormalities in 20–30% of patients on long-term pergolide or cabergoline. Pergolide was withdrawn from the US market in 2007. Cabergoline is still available but restricted for PD in most guidelines. Patients on ergot agonists who cannot be switched require periodic echocardiographic surveillance. Bromocriptine: lower 5-HT2B affinity, lower valvulopathy risk, but now rarely used for PD given availability of superior non-ergot alternatives.
The three non-ergot agonists in current PD practice differ meaningfully in their pharmacokinetic profiles, receptor selectivity, available formulations, and elimination pathways. These differences have direct prescribing consequences, particularly regarding dose adjustment in renal and hepatic impairment and the clinical advantages of extended-release over immediate-release formulations.
Pramipexole is an aminobenzothiazole compound with high selectivity for the D2-family receptors, and the highest relative affinity for D3 among the three agents. It is well absorbed orally, with a bioavailability of approximately 90%, and achieves peak plasma concentrations within 1–3 hours of an immediate-release dose. Food does not significantly alter its bioavailability but delays Tmax. The plasma half-life of pramipexole is 8–12 hours, and it is eliminated almost entirely by renal excretion as unchanged drug, with less than 10% hepatic metabolism. Renal dose adjustment is therefore mandatory: for creatinine clearance of 30–50 mL/min, the maximum dose is halved; for CrCl 15–30 mL/min, the dose is reduced to one-quarter. Pramipexole extended-release (Mirapex ER) provides once-daily dosing with equivalent efficacy to three-times-daily immediate-release pramipexole and produces a flatter plasma concentration profile that may reduce adverse effect peaks and improve dosing convenience. The daily dose is the same when converting from IR to ER formulations; the total daily dose is maintained but distributed differently.4
Ropinirole is a non-ergot D2-family agonist with structural similarity to dopamine and a receptor profile slightly less D3-preferential than pramipexole, though still with greater D3 than D2 affinity. Its oral bioavailability is approximately 50% due to first-pass hepatic metabolism, primarily by CYP1A2. This hepatic CYP1A2 dependence creates a clinically relevant drug interaction: fluvoxamine, an inhibitor of CYP1A2, can increase ropinirole plasma concentrations by up to 80%, potentially precipitating toxicity. Smoking induces CYP1A2 and reduces ropinirole exposure; patients who stop smoking during ropinirole therapy may experience increased ropinirole levels and require dose reduction. The plasma half-life is 6 hours for immediate-release ropinirole, necessitating three-times-daily dosing. Ropinirole extended-release (Requip XL) provides once-daily dosing with a smoother plasma profile; conversion from IR to ER uses the same total daily dose. Unlike pramipexole, ropinirole does not require dose adjustment for renal impairment, as it is primarily hepatically cleared; however, severe hepatic impairment warrants caution and careful dose titration.5
Rotigotine is a non-ergot agonist delivered exclusively as a transdermal patch (Neupro), a formulation that was specifically designed to provide continuous 24-hour drug delivery, bypassing first-pass hepatic metabolism and gastric absorption variability. The patch delivers drug at a constant rate through the skin; plasma concentrations plateau within 24 hours of application and remain stable over the dosing interval. The bioavailability by the transdermal route is approximately 37% of the total patch content, reflecting the skin as an absorptive barrier. Rotigotine undergoes extensive hepatic metabolism, including CYP-mediated conjugation, and its metabolites are excreted in urine and feces; no meaningful renal dose adjustment is required. The plasma half-life reflects the transdermal delivery rate rather than intrinsic drug clearance, effectively achieving a terminal half-life of approximately 5–7 hours after patch removal. Application site reactions — erythema, pruritus, and contact dermatitis — occur in a significant proportion of patients and are managed by daily rotation of patch sites across different skin areas. Rotigotine has particular clinical utility in patients with swallowing difficulties or who are nil per os perioperatively, since it can be maintained transdermally when oral medications must be withheld.6
Pramipexole: renally cleared — mandatory dose reduction for CrCl <50 mL/min. No hepatic adjustment needed. Ropinirole: hepatically cleared via CYP1A2 — no renal dose adjustment; caution in severe hepatic impairment; CYP1A2 interactions (fluvoxamine, smoking). Rotigotine: transdermal, hepatically metabolized — no renal adjustment; use with caution in severe hepatic impairment. All three: elderly patients require slower titration due to increased sensitivity to orthostatic hypotension, somnolence, and cognitive effects.
Apomorphine occupies a distinct position among dopamine agonists. It is the most potent dopamine agonist in clinical use, it acts at both D1 and D2 receptor families unlike the non-ergot oral agonists, and it is administered parenterally rather than orally. Its pharmacological profile — rapid onset, brief duration, and broad receptor activation — makes it uniquely suited both to acute off-episode rescue and to continuous infusion for advanced motor complications.
Despite its name, apomorphine is not an opiate and has no affinity for opioid receptors. The name derives from its chemical synthesis from morphine, but its pharmacological actions are entirely dopaminergic. Apomorphine is a potent full agonist at D1, D2, D3, and D4 receptors, making it the only clinically used dopamine agonist with meaningful D1 activity. This D1 and D2 activation produces a motor response qualitatively similar to levodopa, without the requirement for surviving nigrostriatal terminals or peripheral decarboxylase activity.7 Its broad receptor activity also includes potent agonism at 5-HT2 receptors and antagonism at 5-HT3 receptors, the latter contributing to its antiemetic activity at low doses, though at clinical doses used for PD the net effect is significant nausea requiring antiemetic pretreatment.
The pharmacokinetics of subcutaneous apomorphine are among the most favorable of any antiparkinsonian agent for acute rescue use. Following subcutaneous injection, apomorphine is rapidly absorbed, reaching peak plasma concentrations within 10–20 minutes. Onset of motor effect occurs within 4–12 minutes of injection, and the duration of motor benefit is 45–90 minutes per dose, making it well suited to managing discrete, predictable off episodes. The plasma half-life is approximately 40 minutes, consistent with its brief duration of action. Apomorphine cannot be administered orally because it undergoes extensive and rapid first-pass hepatic metabolism, rendering oral bioavailability negligible. It is available as a subcutaneous pen injection device (Apokyn in the United States) for intermittent rescue use, and as a formulation for continuous subcutaneous infusion via a programmable pump for advanced PD. The pivotal randomized controlled trial of subcutaneous apomorphine rescue injection demonstrated a mean reduction in off-episode duration of approximately 27 minutes per dose, with UPDRS motor score improvement comparable to levodopa rescue at peak effect.8
Antiemetic pretreatment is required when initiating apomorphine rescue therapy. Domperidone 20 mg three times daily, started 3 days before the first apomorphine dose and continued for several weeks, effectively prevents the nausea and vomiting that would otherwise accompany treatment initiation. Ondansetron and other 5-HT3 antagonists should not be used as antiemetics with apomorphine, because apomorphine itself has 5-HT3 antagonist properties and combined 5-HT3 blockade may contribute to QT prolongation — a combination that has been associated with cardiac arrhythmias including torsades de pointes in case reports.9 Domperidone, the preferred antiemetic, does not carry this interaction. Once tolerance to apomorphine's emetogenic effect develops over several weeks of titration, domperidone can usually be tapered and discontinued, and most patients no longer require it during maintenance therapy.
Continuous subcutaneous apomorphine infusion (CSAI) delivers the drug via a programmable pump over 12–16 waking hours, analogous to the continuous levodopa delivery achieved with intestinal gel but without requiring surgical PEG-J tube placement. CSAI provides effective continuous dopaminergic stimulation and substantially reduces both off time and dyskinesias in patients with advanced PD and refractory motor complications. Observational studies and prospective series report reductions in off time of 50–70% and reductions in levodopa equivalent dose of 30–50% in patients successfully established on CSAI.10 The principal limiting adverse effects of CSAI are skin nodules and indurations at injection sites, which develop in most patients with long-term use and can eventually limit viable injection areas; this complication is managed by systematic site rotation, ultrasound-guided site selection, and, in refractory cases, by switching to LCIG. Subcutaneous necrosis and, rarely, hemolytic anemia due to a Coombs-positive immune reaction are additional concerns with long-term CSAI.
Ondansetron and other 5-HT3 antagonists are contraindicated with apomorphine. The combination has been associated with severe hypotension and loss of consciousness in case reports, and the combined 5-HT3 blockade prolongs QTc. Domperidone is the antiemetic of choice for apomorphine-treated patients. If domperidone is unavailable (as it is in the United States), trimethobenzamide may be used. Metoclopramide is contraindicated in PD as it blocks central D2 receptors and worsens motor function.
Dopamine agonists occupy two distinct clinical roles in PD pharmacotherapy: as initial monotherapy in early disease, particularly in younger patients, and as adjunctive therapy added to levodopa when wearing-off or dyskinesias emerge. The evidence base for each role is well established, but the long-term comparative trials reveal important nuances about what agonist-first strategies actually achieve, and what they do not.
The rationale for initiating a dopamine agonist rather than levodopa in early PD, particularly in patients younger than approximately 60 years, rests on two clinical observations. First, dopamine agonists produce fewer early dyskinesias than levodopa when used as initial therapy over the first 2–5 years. The pivotal randomized trials comparing ropinirole versus levodopa (056 Study Group) and pramipexole versus levodopa (Parkinson Study Group) both demonstrated that initial agonist therapy was associated with lower rates of dyskinesia development at 5 years: approximately 20% with ropinirole versus 45% with levodopa, and approximately 10% with pramipexole versus 31% with levodopa as initial therapy.11 Second, dopamine agonists have lower motor complication-inducing potential than levodopa, reflecting their more continuous receptor stimulation and lower intrinsic propensity for receptor sensitization.
However, these apparent advantages of agonist-first therapy require important qualification. Both pivotal trials allowed rescue levodopa to be added when motor control was insufficient, and the majority of agonist-treated patients required levodopa supplementation within 2–3 years. The lower dyskinesia rates in agonist-treated patients at 5 years reflect, at least in part, lower total cumulative levodopa exposure rather than a durable neuroprotective or receptor-sensitization-preventing effect of agonists themselves. When total levodopa equivalent dose is controlled across years, the difference in dyskinesia rates narrows substantially. Furthermore, patients who began on agonists and subsequently added levodopa did not have substantially better long-term motor outcomes at 5 years compared with those who began on levodopa and continued it, and the cognitive and impulse control adverse effects of agonists were more prominent in older patients, limiting the applicability of agonist-first strategies to the younger patient group.12
When used as adjunctive therapy in patients with motor fluctuations on levodopa, dopamine agonists consistently reduce off time by approximately 1–2 hours per day and allow levodopa dose reduction of 10–30%, without proportionately worsening motor control in patients who tolerate the addition. Extended-release formulations — pramipexole ER and ropinirole ER — have demonstrated non-inferiority to their immediate-release equivalents in terms of efficacy, with improved convenience and potentially better compliance. The addition of a dopamine agonist as adjunct is the fourth step in the wearing-off management algorithm (following dose interval shortening, COMT inhibitor, and MAO-B inhibitor addition), and is particularly valuable in patients whose wearing-off is not adequately controlled by levodopa optimization alone.
The decision to initiate a dopamine agonist rather than levodopa in newly diagnosed PD is guided by age and cognitive status, not diagnosis alone. In patients under approximately 60 years at diagnosis, with preserved cognition and no contraindications, agonist-first is a reasonable strategy that delays dyskinesia onset relative to levodopa initiation. In patients over approximately 70 years, the cognitive, somnolence, and impulse control risks of agonists outweigh the dyskinesia-prevention benefit given the shorter expected disease course, and levodopa is preferred. Patients between 60 and 70 require individualized assessment. These age thresholds are guidelines, not rules; frailty, comorbidities, and patient preference are equally important considerations.
Dopamine agonists share a class-wide adverse effect profile that is distinct from levodopa and reflects their D3-preferential limbic receptor activity. While some adverse effects — nausea, orthostatic hypotension, dizziness — overlap with levodopa and are managed similarly, others — impulse control disorders, excessive daytime somnolence, and dopamine dysregulation syndrome — are agonist-specific and require dedicated monitoring and management strategies.
Impulse control disorders (ICDs) are the most clinically significant class-specific adverse effect of dopamine agonists. They encompass a spectrum of compulsive, reward-seeking behaviors including pathological gambling, hypersexuality, compulsive shopping, and binge eating, occurring in 10–20% of patients on therapeutic doses of dopamine agonists.13 The pathophysiology reflects D3 receptor-mediated overactivation of the mesolimbic reward pathway, particularly the nucleus accumbens and its prefrontal cortical connections. D3 receptors have higher affinity for dopamine agonists than D2 receptors, and the limbic D3 activity produces reward sensitization that can develop into compulsive behavior. ICDs are more prevalent with higher agonist doses, younger age, male sex, a personal or family history of addictive behaviors, and in patients on higher-dose agonist therapy; they can occur at any therapeutic dose and patients on agonist therapy should be screened at each visit with specific questions about behavioral changes. The management of ICDs requires agonist dose reduction or discontinuation; in patients who cannot tolerate agonist withdrawal because of loss of motor control, clozapine or other antidopaminergic strategies have been used with variable success, and DBS may reduce the agonist requirement sufficiently to allow ICD control.
Excessive daytime somnolence (EDS) and sudden sleep attacks are reported in a significant proportion of patients on dopamine agonists, with rates varying from 15% to over 50% depending on the study and the definition used. Sleep attacks — episodes of sudden irresistible sleep without warning — have been reported during driving and other activities requiring sustained alertness, with serious consequences in several published cases. All patients initiating dopamine agonist therapy should be warned about the risk of sudden sleep onset, advised to assess their alertness before driving or operating machinery, and instructed to contact their prescriber if episodes of EDS or sudden sleep occur. Polysomnographic studies have demonstrated that agonists alter REM sleep architecture, and EDS is more common in patients with pre-existing fatigue, insomnia, or sleep disorders. Dose reduction is the primary management strategy; if EDS persists despite dose reduction, a switch to a different agonist or cessation of agonist therapy may be necessary.14
Dopamine dysregulation syndrome (DDS) is a compulsive overuse of dopaminergic medications, most commonly levodopa, that occurs in a small subset of PD patients and shares pathophysiological features with substance addiction. Patients with DDS take dopaminergic medications in excess of the doses required for motor control, driven by the hedonic and stimulant-like effects of the drugs in the mesolimbic system, and they resist dose reduction even when dyskinesias and psychiatric side effects are severe. DDS is associated with young onset PD, male sex, depression, impulsive personality traits, and prior history of substance misuse. Management requires a structured dose-reduction program, behavioral support, and sometimes psychiatric co-management; it is distinct from ICD in that the compulsive behavior targets the medications themselves rather than external reward activities, though DDS and ICD frequently co-exist in the same patient.15
Peripheral edema, affecting the legs and ankles, occurs in 10–15% of patients on dopamine agonists, reflecting peripheral vasodilation and altered capillary permeability. It is usually mild and responds to dose reduction; diuretics are generally not effective and not recommended as the primary management. Hallucinations and confusion occur more commonly in older patients, in those with pre-existing cognitive impairment, and in those on higher doses. When hallucinations occur in an agonist-treated patient, agonist dose reduction or discontinuation should be the first intervention before adding an antipsychotic, since the hallucinations are drug-induced and often resolve with dose reduction. If antipsychotic therapy is needed, only quetiapine or clozapine should be used in PD, as all other antipsychotics block central D2 receptors and worsen motor function.14
ICDs are frequently not volunteered by patients due to shame or lack of awareness that the behaviors are medication-related. At every visit for patients on dopamine agonists, specifically ask about: changes in gambling behavior or spending; changes in sexual behavior or preoccupation; changes in eating patterns or relationship with food; and hours spent on repetitive activities such as collecting, sorting, or Internet use. The QUIP (Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease) is a validated screening tool. Identifying ICDs early, before significant financial, relational, or legal consequences occur, is a central component of safe dopamine agonist prescribing.
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356(1):39–46.
doi:10.1056/NEJMoa054830Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990;347(6289):146–151.
doi:10.1038/347146a0Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484–1491.
doi:10.1056/NEJM200005183422004Schapira AH, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011;77(8):767–774.
doi:10.1212/WNL.0b013e31822affdbKaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000;39(4):243–254.
doi:10.2165/00003088-200039040-00001LeWitt PA, Lyons KE, Pahwa R; SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology. 2007;68(16):1262–1267.
doi:10.1212/01.wnl.0000259516.61938.bbJenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology. 2002;58(4 Suppl 1):S1–S8.
doi:10.1212/WNL.58.suppl_1.S1Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58(9):1385–1392.
doi:10.1001/archneur.58.9.1385Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology. 2004;62(6 Suppl 4):S12–S17. [Antiemetic selection and 5-HT3 antagonist contraindication in the context of the US apomorphine program.]
doi:10.1212/WNL.62.6_suppl_4.S12Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord. 2005;20(2):151–157.
doi:10.1002/mds.20276Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044–1053.
doi:10.1001/archneur.61.7.1044Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ; Parkinson's Disease Research Group of the United Kingdom. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008;71(7):474–480.
doi:10.1212/01.wnl.0000310812.43352.66Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–595.
doi:10.1001/archneurol.2010.65Hobson DE, Lang AE, Martin WRW, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002;287(4):455–463.
doi:10.1001/jama.287.4.455Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423–428.
doi:10.1136/jnnp.68.4.423